Compare OLB & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLB | ACXP |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.9M |
| IPO Year | 2019 | 2021 |
| Metric | OLB | ACXP |
|---|---|---|
| Price | $0.34 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $95.50 |
| AVG Volume (30 Days) | ★ 142.3K | 78.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,676,907.00 | N/A |
| Revenue This Year | $12.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.29 |
| 52 Week High | $1.85 | $8.34 |
| Indicator | OLB | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 29.48 | 43.91 |
| Support Level | $0.31 | $1.37 |
| Resistance Level | $0.59 | $1.75 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 6.55 | 39.02 |
The OLB Group Inc is a diversified FinTech company that focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. The company seeks to provide merchants with a wide range-of-products and services through the various online platforms, including financial and transaction processing services. It also has products that provide support for crowdfunding and other capital-raising initiatives. It supplements the online platforms with certain hardware solutions that are integrated with the online platforms. The company has two business segments: Fintech Services, which generates key revenue, and the Bitcoin Mining business segment.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.